Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
- 12 November 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Abstract
Background: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long‐term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. Methods: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno‐associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail‐cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension‐associated comorbidities were examined through histological analysis and ELISA. A modified N‐acetylgalactosamine‐conjugated small interfering RNA targeting human hepatic AGT (GalNAc‐siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. Results: The dual adeno‐associated virus‐induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc‐siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc‐siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio‐ and renoprotective effects. Moreover, combining GalNAc‐siAGT with the renin‐angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. Conclusions: Our study validated the antihypertensive therapeutic effect of GalNAc‐siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.This publication has 60 references indexed in Scilit:
- LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activityCell Reports, 2021
- RNA-Targeted TherapeuticsCell Metabolism, 2018
- Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid TherapeuticsMolecular Therapy Nucleic Acids, 2017
- Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applicationsJournal of Controlled Release, 2015
- Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its EffectivenessAmerican Journal of Hypertension, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With ValsartanAmerican Journal of Hypertension, 2007
- RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal diseaseCurrent Hypertension Reports, 2003
- The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: development of lesions and morphometric analysisVirchows Archiv, 1998
- Immunocytochemical localization of angiotensinogen in rat liver and kidneyCell and tissue research, 1983